<DOC>
	<DOCNO>NCT00356915</DOCNO>
	<brief_summary>Onychomycosis common condition accounting approximately half nail disorder . It commonly cause dermatophytes . Itraconazole approve treatment onychomycosis United States approve dosage regimen treatment onychomycosis toenail daily ( QD ) treatment 200mg itraconazole ( two 100 mg capsule ) 12 week . Barrier Therapeutics develop 200 mg tablet could use convenient one-tablet-per-day dose regimen . This clinical trial compare efficacy safety new tablet formulation itraconazole capsule placebo .</brief_summary>
	<brief_title>Itraconazole Tablets Vs. Itraconazole Capsules v . Placebo Onychomycosis Toenail .</brief_title>
	<detailed_description>Onychomycosis common account half nail disorder . Usually cause due dermatophytes , either Trichophyton rubrum ( 71 % ) Trichophyton mentagrophytes ( 20 % ) may also due yeast infection , usually Candida albicans . The prevalence onychomycosis United States population whole 13 % prevalent elderly ( 60 % ) . Onychomycosis toenail recurs think genetic component . Onychomycosis result permanent nail deformity . This disease significant impact patient 's quality life ( e.g. , concern appearance toenail fingernail , interference wearing shoe , walk sport activity ) . Itraconazole approve treatment onychomycosis United States since mid-nineteen-nineties . The approved dosage regimen treatment onychomycosis toenail daily ( QD ) treatment 200 mg itraconazole ( Sporanox® , Janssen Pharmaceutical Products , L.P. , Titusville , NJ , USA ) 12 week . The approved dosage form 100mg capsule . Barrier Therapeutics develop 200mg tablet could use convenient one-tablet-per-day dose regimen . This clinical trial compare efficacy safety new tablet formulation itraconazole capsule placebo .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Clinical diagnosis onychomycosis least one great toenail Percent Nail Involvement Score severely affect great toenail ( Target Toenail ) must 2 3 ( 2575 % nail unit ) . Length Unaffected Part Target Toenail ≥2mm Direct microscopic examination KOH positive hypha associate dermatophytes target toenail Subjects must sign inform consent If subject woman childbearing potential , must negative urine pregnancy test agree use effective form birth control first menses 60 day follow last dose study medication . Onychomycosis cause Candida spp . without presence dermatophyte Participation clinical trial systemic treatment onychomycosis toenail within 24 week prior Visit 1 Use systemic antifungal within 12 week prior Visit 1 Use topical antifungal nail lacquer within 30 day prior Visit 1 Use topical onychomycosis treatment toenail within 7 day prior Visit 1 Evidence ventricular dysfunction congestive heart failure ( CHF ) history CHF Known liver disease history liver toxicity drug Use systemic immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Nail fungus</keyword>
	<keyword>Onychomycosis</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Toenail</keyword>
</DOC>